Dose-escalation data show favorable safety profile and promising clinical activity for IPH4102
Innate Pharma strengthens its proprietary pipeline with the acquisition of anti-C5aR, a first-in-class clinical-stage antibody,from Novo Nordisk A/S
Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017
IPH4102: Completion of the dose escalation part of the Phase I trial - Data to be presented at International Conference on Malignant Lymphoma in June 2017 in Lugano
First quarter 2017 report
Number of shares and voting rights of Innate Pharma as at May 5, 2017
Number of shares and voting rights of Innate Pharma as at april 4, 2017
Innate Pharma: 2016 reference document made available (in french)
Expansion of Phase I/II trial evaluating lirilumab in combination with Opdivo (nivolumab) in patients with advanced solid tumors
2016: Operational progress and robust financial position for further growth
